FHTX · Foghorn Therapeutics Inc.
Market Cap
$369.38M
Shares
59.39M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.00
Open$6.17
Day$5.96–6.24
52W close$3.53–7.07
Avg vol 30d292K
Short int1.8M · 3.0% float · 7.1d
Short vol36%
Last earningsAug 10, 2021
DataOct 2020–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
+9%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
70%
mid-range
Momentum
relative strength
1-month return
+32%
trailing
6-month return
+9%
trailing
YTD return
+11%
this year
Relative strength
−4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow
Distributing
-2% holders QoQ · +15 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.01% of float · ▲ +11.4% MoM · 7.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
103 holders — near 3-yr high, broad support
Squeeze score
61
elevated · 0–100
Fundamentals
Revenue growth
+37%
Y/Y
EPS growth
+25%
Y/Y
Free cash flow
$-86.1M
Balance sheet
$73.1M
net cash
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−46%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jan 12, 2026
Cash, cash equivalents, and marketable securities
· As of January 13, 2026
$208.9M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
70%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow
Distributing
-2% holders QoQ · +15 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.01% of float · ▲ +11.4% MoM · 7.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
103 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $6 · 70%
Range high $7
vs 200-day avg +18%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FHTX
this stock
Foghorn Therapeutics Inc.
|
$369.38M | +11.1% | +36.8% | — | 3.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +2.9% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FHTX | -15.1% | +32.5% | +9.5% | +32.5% | +11.1% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -15.6% | +29.5% | -3.9% | +29.5% | -1.7% |
Key facts
CIK
1822462
CUSIP
344174107
13F (30d)
86 filings
86 filers
Visit website
Investor relations